In the IMMINENT cohort, co-occurrences were also significant with RB1; patients with EGFR/RB1/TP53 co-mutant lung cancer are at risk of small or large cell neuroendocrine lung cancer transformation (37, 38). Here, EGFR is linked to lung carcinoma.